Valuation: Carlsmed, Inc.

Market Cap 342M 297M 276M 254M 480M 32.65B 487M 3.25B 1.28B 16.26B 1.29B 1.26B 53.87B P/E 2026 *
-8.29x
P/E 2027 * -8.53x
Enterprise Value 342M 297M 276M 254M 480M 32.65B 487M 3.25B 1.28B 16.26B 1.29B 1.26B 53.87B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 3.26x
Free-Float
56.16%
Yield 2026 *
-
Yield 2027 * -
1 day-0.55%
1 week+16.57%
1 month+21.29%
3 months+41.62%
6 months+1.37%
Current year+1.94%
1 week 10.99
Extreme 10.99
13.02
1 month 9.91
Extreme 9.91
13.06
Current year 8.5
Extreme 8.5
15.19
1 year 8.5
Extreme 8.5
17.19
3 years 8.5
Extreme 8.5
17.19
5 years 8.5
Extreme 8.5
17.19
10 years 8.5
Extreme 8.5
17.19
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 50 2018-06-03
Chief Executive Officer 50 2018-06-03
Director of Finance/CFO 50 2023-07-31
Director TitleAgeSince
Chairman 50 2018-06-03
Director/Board Member 50 2018-06-03
Director/Board Member 66 2020-12-15
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Free

Executive/Senior Manager

44,977 0.1692%
1/28/26 Free

Founder

44,977 0.1692%
1/28/26 Free

Chief Executive Officer

117,316 0.4414%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%+16.57%-10.46% - 342M
+0.09%+2.56%-16.24%-5.06% 183B
-0.37%+2.62%-5.37%-2.70% 109B
-0.29%+0.47%+8.83%+66.58% 60.57B
+3.50%+0.47%+28.65%+49.27% 51.8B
+0.10%+5.92%-7.09%-40.56% 45.64B
+0.41%+1.37% - - 33.22B
+11.95%+16.65%+3.32%-33.00% 31.49B
+0.40%+3.89%+42.51%-7.36% 24B
-1.22%+6.69%+0.84%+1.26% 22.26B
Average +1.40%+6.03%+5.00%+3.56% 56.15B
Weighted average by Cap. +0.92%+3.50%-1.37%+4.41%

Financials

2026 *2027 *
Net sales 74.83M 64.91M 60.42M 55.51M 105M 7.14B 107M 712M 279M 3.55B 281M 275M 11.78B 105M 91.04M 84.74M 77.86M 147M 10.01B 149M 998M 392M 4.99B 394M 385M 16.52B
Net income -40.95M -35.52M -33.06M -30.38M -57.4M -3.91B -58.32M -389M -153M -1.95B -154M -150M -6.45B -40.62M -35.23M -32.79M -30.13M -56.93M -3.87B -57.85M -386M -152M -1.93B -153M -149M -6.39B
Net Debt - -
Logo Carlsmed, Inc.
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
Employees
127
Date Price Change Volume
26-07-31 US$12.59 -0.55% 79,662
26-07-30 US$12.66 -0.94% 126,055
26-07-29 US$12.78 +3.82% 138,194
26-07-28 US$12.31 +7.51% 150,727
26-07-27 US$11.45 +6.02% 46,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.59USD
Average target price
18.60USD
Spread / Average Target
+47.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CARL Stock